When discussions of modern psilocybin research begin, they almost always begin with Johns Hopkins. The Center for Psychedelic and Consciousness Research at Johns Hopkins University was the first formal academic center of its kind in the United States, and the team there — led for many years by Roland Griffiths until his death in 2023 — has produced more peer-reviewed psilocybin research than any other Western institution. Their work has shaped both the scientific conversation and the regulatory pathway that psilocybin is currently traveling.
This article walks through what the Hopkins team has actually done. We cover their core methodology, their main published findings across several clinical and consciousness-research domains, and the careful limits the researchers themselves place on their conclusions. We do not editorialize about whether psilocybin “should” be a medicine. We focus on what the published data can and cannot support.
The Modern Era Begins, 2006
The contemporary psilocybin research era is conventionally dated to 2006, when Roland Griffiths and colleagues published “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance” in Psychopharmacology. The study itself was small — 36 healthy volunteers, none of them with prior psychedelic experience — and the methodology was conservative.
The structure was simple. Participants received either psilocybin or methylphenidate (Ritalin) in carefully matched sessions. Sessions took place in a comfortable, living-room-like environment, with two trained monitors present throughout. Participants were instructed to focus on their inner experience, with music playing and eyeshades worn to limit external input. Outcomes were measured through standardized questionnaires, including the Mystical Experience Questionnaire and the Hood Mysticism Scale.
The results were notable not because of any clinical claim — this was a healthy-volunteer study, not a treatment trial — but because of the structure of the experiences participants described and the persistence of their effects. Two months after their psilocybin sessions, 67% of participants rated the experience as among the five most personally meaningful of their lives. 33% rated it the single most meaningful experience. These ratings were unprecedented in the experimental literature of human consciousness.
The 2006 paper did not prove that psilocybin had medical applications. It did, however, demonstrate that the drug could be administered in a controlled research setting with predictable subjective effects, that those effects had structural features researchers could measure, and that the subjective intensity was sufficient to merit further clinical investigation. It re-opened a research literature that had been effectively frozen since the early 1970s.
The Methodology in Detail
The Hopkins model for psilocybin sessions has become the de facto standard for psychedelic clinical research worldwide. The components are worth understanding because they affect how the resulting data should be interpreted.
Screening. Participants are extensively screened before enrollment. Standard exclusion criteria include personal or family history of schizophrenia or other psychotic disorders, bipolar I disorder, current substance use disorder, cardiovascular disease that would make blood pressure spikes unsafe, and pregnancy. These exclusions matter because they shape who the findings apply to. The Hopkins data cannot, by design, tell us how psilocybin would affect populations who were screened out.
Preparation. Before any session, participants meet repeatedly with the monitors who will accompany them. These preparation sessions typically include eight or more hours of conversation, building rapport and discussing what the participant hopes for and fears. This is not casual. Preparation is considered structurally essential to outcomes, both for safety and for the depth of the experience.
Setting. Sessions occur in a dedicated room designed to feel domestic rather than clinical. Soft lighting, comfortable furniture, art on the walls, no overt medical equipment beyond what is needed for monitoring. Two trained monitors are present continuously for the six-to-eight hours of acute drug effects. Participants are encouraged to wear eyeshades, listen to a curated music playlist, and focus on internal experience.
Dosing. Hopkins has typically used doses in the range of 20–30 mg of synthetic psilocybin per 70 kg of body weight. These are substantial doses, designed to reliably produce intense subjective effects. Lower doses are used in some specific protocols, but the standard “full-dose” research sessions involve experiences participants regularly describe as the most intense of their lives.
Integration. Following the session, participants meet again with their monitors over the subsequent days and weeks to discuss what occurred and to integrate it into their ongoing lives. This phase is considered as important as the drug session itself. In clinical trials for specific conditions, integration sessions are explicitly therapeutic.
This whole package — screening, preparation, setting, dosing, integration — is the protocol. The drug is one ingredient. When researchers and journalists discuss “psilocybin trials,” what they are studying is rarely the drug alone. It is psilocybin embedded in a psychotherapeutic protocol. The distinction matters because applying the drug outside that protocol does not necessarily produce the same outcomes.
The Cancer Anxiety Study, 2016
In 2016, Griffiths and colleagues published a randomized double-blind trial of psilocybin for depression and anxiety in patients with life-threatening cancer. The study enrolled 51 participants and compared a high-dose psilocybin session (22 mg/70 kg) to a low-dose control (1 or 3 mg/70 kg), with crossover design.
Six months after the high-dose session, 65–80% of participants showed clinically significant reductions in depression and anxiety symptoms, with effect sizes that would be considered large by the standards of psychiatric trials. A parallel study by Stephen Ross and colleagues at NYU, published in the same issue of the Journal of Psychopharmacology, found similar results in a separate cohort.
These were not pilot studies in the rough sense. They used validated outcome measures, included matched controls, were peer-reviewed, and produced effect sizes that, taken at face value, were striking. They also had significant methodological limitations that the authors themselves discussed in detail.
The participants could in nearly all cases tell which condition they had received. A “double-blind” trial only blinds participants if the conditions feel similar, and a high-dose psilocybin session feels nothing like a 1 mg dose. This is the functional unblinding problem that haunts essentially all psychedelic research. It means we cannot rule out that some portion of the observed benefit reflects expectancy, placebo, or the structure of the therapeutic relationship rather than a specific drug effect.
The samples were also small, the participants self-selected, and the populations relatively homogeneous. None of these factors invalidate the findings. They simply set bounds on how confidently we can generalize.
Major Depressive Disorder, 2020
In 2020, the Hopkins team published a small open-label and randomized trial of psilocybin for major depressive disorder — a more common condition than treatment-resistant depression or cancer-related distress. The trial used a two-session psilocybin protocol with a delayed-treatment control group.
The results showed clinically significant reductions in depressive symptoms in the immediate-treatment group, with effects persisting at one-month follow-up. Subsequent reports tracked some participants out to twelve months and found that benefits, in many cases, were maintained.
Again, the same caveats apply. The trial was small (24 participants in the published cohort). Unblinding was extensive. There was no active comparator that would have controlled for the intensity of the psilocybin experience. The therapeutic protocol surrounding the drug was substantial. We cannot, from this study alone, isolate the contribution of psilocybin itself from the contribution of the surrounding therapy.
But the trial established something more modest and arguably more important: that psilocybin-assisted therapy for major depression is feasible to run in a controlled academic setting, that adverse events were limited and manageable, and that the magnitude of observed effect was large enough to justify larger, better-controlled studies. Those larger trials are now underway through multiple sponsors, both academic and commercial.
Tobacco Cessation
A different line of Hopkins research, led by Matthew Johnson, has investigated psilocybin for smoking cessation. The published 2014 pilot study enrolled 15 long-term smokers who had failed previous quit attempts. They received two or three psilocybin sessions embedded in a cognitive-behavioral therapy program.
Six months after treatment, 80% of participants were biochemically verified as abstinent. At 12-month follow-up, 67% remained abstinent. These rates are substantially higher than the 30–40% six-month abstinence rates achieved by best-available pharmacological treatments such as varenicline.
The study was open-label with no control group. It was tiny. It was not designed to support a regulatory claim. What it did was provide enough preliminary evidence to justify the larger randomized controlled trials of psilocybin for substance use disorder now underway at Hopkins and elsewhere.
Mystical Experience and the Question of Mechanism
One of the more philosophically interesting lines of Hopkins research concerns the mediation of clinical effects. Across multiple studies, the team has found that the degree to which participants report having a “mystical-type experience” during their dosing session — as measured by the Mystical Experience Questionnaire — correlates with the magnitude of long-term clinical benefit.
This is a striking finding because it suggests that the drug alone is not what produces the benefit. The drug produces an experience; the experience appears to mediate the change.
This finding has been replicated across several conditions and several research groups. It is the strongest evidence we have for the hypothesis that psilocybin’s therapeutic potential is experiential rather than purely pharmacological. It also raises a regulatory and ethical question: if the benefit depends on the subjective experience, then what counts as a “treatment” cannot be specified in milligrams alone.
The Hopkins team has been careful about overclaiming on this point. The correlation is consistent. Whether the mystical experience is causally necessary for clinical benefit, or merely a correlate of other underlying processes, remains undetermined.
Limitations the Researchers Themselves Emphasize
In reading Hopkins papers, one notices something distinctive: the limitations sections are often longer and more candid than is typical in psychiatric research. The team’s own framing of their findings is worth quoting in spirit.
The trials are small. The samples are self-selected — participants who agree to take a powerful psychedelic in a research setting are not a random cross-section of clinical populations. Blinding is functionally impossible. Active comparators that mimic the intensity of psilocybin are rare. Long-term follow-up beyond a year is limited. Adverse event monitoring captures medical events but is less precise about psychological events that participants do not report. And the bundling of drug and therapy makes mechanistic claims difficult.
What the Hopkins team has consistently maintained is that their data justify continued investigation, not regulatory approval. The trials that would constitute a sufficient evidence base for general clinical use — large, multi-site, placebo-controlled with credible active comparators, long-term follow-up — are now underway. They are not Hopkins trials alone. They involve a broad consortium of academic and commercial research centers.
What the Hopkins Era Has Established
Stepping back from individual studies, what has the Hopkins program established as solid?
It has established that psilocybin can be administered safely in a controlled research setting to carefully screened populations. Serious adverse events in published trials have been rare and manageable, and the drug does not appear to produce dependence or compulsive use patterns.
It has established that psilocybin produces predictable, structured subjective experiences that can be measured with validated instruments.
It has established that, in several clinical populations, psilocybin-assisted therapy produces effect sizes that are large by the standards of psychiatric medicine.
It has established that the magnitude of subjective experience appears to mediate the magnitude of clinical effect.
What it has not established is that psilocybin is ready for general clinical use, that its benefits can be expected to extend to populations not yet studied, that the drug alone is sufficient without the surrounding therapeutic protocol, or that the long-term safety profile is fully characterized.
This is the standard, careful research-evidence stance: enough is known to justify more study; not enough is known to make general medical recommendations.
How to Read New Hopkins Studies
Several principles will help anyone trying to read this research as it continues to develop.
Look at the sample size and selection criteria first. Findings from a tightly screened sample of 25 participants do not yet tell us what to expect in a general population of 25,000.
Look for active comparators. Many psychedelic trials still use placebos so distinct from the psilocybin condition that participants and clinicians can tell which is which. This unblinding inflates apparent effects. Trials that use lower doses of psilocybin, ketamine, or other psychoactive comparators provide stronger evidence.
Look at the integration protocol. The dose is one variable. The therapeutic relationship and follow-up structure are also variables. A trial that strips the integration sessions to a minimum is testing a different thing than a trial with extensive integration support.
Look at the funding source. Several recent trials are sponsored by pharmaceutical companies with commercial interests in approval. This does not invalidate findings, but it should affect how one reads press releases and what to ask for in the published methods.
And, finally, read the limitations sections. They are often the most useful part of the paper.
A Closing Note
Roland Griffiths died in late 2023 after a public diagnosis of cancer. In his final years, he spoke openly about his own engagement with the questions his research had raised. The program he built outlasts him, and continues to produce careful work.
The Hopkins program represents a distinctive model in contemporary biomedical research: a research center investigating a substance that, for half a century, was legally classified as having no medical use, conducted with methodological rigor and unusual candor about uncertainty. Whether that program ultimately produces approved medical applications for psilocybin will depend on data that are still being generated. What it has already produced is a framework for studying the drug honestly, in a literature that has historically been more vulnerable to overclaim than most.
This article is part of the Magic Mushroom Institute’s research literacy series. We summarize clinical research for general readers and emphasize the limits of current evidence. Last reviewed May 2026.